While the findings and clinical trials for anti-LINGO-1 antibodies revolve around demyelinating conditions such as MS, anti-LINGO-1 does present another potential therapeutic opportunity for the treatment of SCI. This evidence concerns the gene LINGO1 and myeloid sarcoma.